The Cash Ratio measures a company’s ability to meet its short-term obligations with cash and near-cash resources. It is calculated as a company's Cash, Cash Equivalents, Marketable Securities divides by its Total Current Liabilities. VistaGen Therapeutics's Cash Ratio for the quarter that ended in Dec. 2021 was 13.04.
VistaGen Therapeutics has a Cash Ratio of 13.04. It generally indicates that the company is able to cover all short-term debt and still have cash remaining.
The historical rank and industry rank for VistaGen Therapeutics's Cash Ratio or its related term are showing as below:
VTGN'
s Cash Ratio Range Over the Past 10 Years
Min: 0.01 Med: 1 Max: 35
Current: 13.04
During the past 13 years, VistaGen Therapeutics's highest Cash Ratio was 35.00. The lowest was 0.01. And the median was 1.00.
VTGN's Cash Ratio is ranked better than 79.51% of 1484
companies
in the Biotechnology industry
Industry Median: 4.99
vs VTGN: 13.04
VistaGen Therapeutics Cash Ratio Historical Data
The historical data trend for VistaGen Therapeutics's Cash Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* Premium members only.
VistaGen Therapeutics Annual Data
Trend
Mar12
Mar13
Mar14
Mar15
Mar16
Mar17
Mar18
Mar19
Mar20
Mar21
Cash Ratio
2.14
7.11
4.68
0.49
24.61
VistaGen Therapeutics Quarterly Data
Mar17
Jun17
Sep17
Dec17
Mar18
Jun18
Sep18
Dec18
Mar19
Jun19
Sep19
Dec19
Mar20
Jun20
Sep20
Dec20
Mar21
Jun21
Sep21
Dec21
Cash Ratio
35.00
24.61
15.60
11.83
13.04
Competitive Comparison
For the Biotechnology subindustry, VistaGen Therapeutics's Cash Ratio, along with its competitors' market caps and Cash Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
VistaGen Therapeutics Cash Ratio Distribution
For the Biotechnology industry and Healthcare sector, VistaGen Therapeutics's Cash Ratio distribution charts can be found below:
* The bar in red indicates where VistaGen Therapeutics's Cash Ratio falls into.
VistaGen Therapeutics Cash Ratio Calculation
The Cash Ratio measures a company's ability to meet its short-term obligations with its cash and near-cash resources.
VistaGen Therapeutics's Cash Ratio for the fiscal year that ended in Mar. 2021 is calculated as:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
VistaGen Therapeutics (NAS:VTGN) Cash Ratio Explanation
The cash ratio is more conservative than other liquidity ratios, such as Quick Ratio and Current Ratio, because it only considers a company's most liquid resources. The numerator of cash ratio only considers Cash, Cash Equivalents and marketable securities. Other current assets, such as accounts receivable and inventories, are not included. The rationale is that these assets may require time to be transformed into cash, and the amount of money received is also uncertain.
The cash ratio shows a company’s ability to pay all current liabilities immediately without selling or liquidating other assets. Generally speaking, a higher cash ratio suggests the company has a stronger ability to cover its short-term debt. However, a high cash ratio could also indicate inefficient management: the company is inefficient in making full utilization of cash to invest protential profitable project. It may also suggest that the company is not confident about future profitability.
In general, the higher the cash ratio, the better the company's liquidity position.
VistaGen Therapeutics Cash Ratio Related Terms
Thank you for viewing the detailed overview of VistaGen Therapeutics's Cash Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.
VistaGen Therapeutics Inc is a biotechnology firm. The company is in its clinical stage and engaged in developing and commercializing product candidates for patients with diseases and disorders involving the central nervous system. Its lead product candidate, AV-101, is an orally available prodrug candidate in Phase II development, initially for the adjunctive treatment of a major depressive disorder in patients with an inadequate response to standard antidepressants. The PH94B is a novel neuroactive nasal spray with therapeutic potential in a wide range of indications involving anxiety or phobia; PH10 is an odorless, fast-acting synthetic neurosteroid for neuropsychiatric indications involving depression.
My Portfolios
Create New Portfolio
Portfolio Contest
My Gurus
Personalize
Premium Gurus 
0(0%) Volume: 308,597 1:26PM EDT
Email Alerts
Stock PDF
RSS
Website
Filings
Download
Manual of Stocks™ Web APP
NAS:VTGN has been successfully added to your 
